Skip to main content
Healthcare

STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive

STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive

Feed excerpt — reported by STAT News

Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.